InsidersTradesSigma
Follow the Pediatrix Medical Group, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pediatrix Medical Group, Inc. has recorded 89 reports. Market capitalisation: €2.2bn. The latest transaction was disclosed on 18 August 2026 (Disposition). Among the most active insiders: Moore Mary Ann E. Every trade is accessible without an account.
89
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€5m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pediatrix Medical Group, Inc. Buy (bullish), based on 6 analysts. Average price target: US$26.17.
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,082 of 28,752 companies
66.1
score / 100
Value74
Quality58
FCF yld12%
Earn yld7.7%
EV/EBITDA10.2x
ROE20%
Gross mgn26%
Net mgn8.6%
Debt/EBITDA2.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations89 total
18,500 shares@ US$26.62Common StockSEC:0001193125-26-355656:0
18,500 shares@ US$26.58750.023% mcap100.0% of flowCommonSEC144:0001628280-26-057186
472 shares@ US$26.500.0006% mcap4.0% of flowCommon StockSEC:0001193125-26-352527:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352534:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352528:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352522:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352524:0
472 shares@ US$26.500.0006% mcap1.1% of flowCommon StockSEC:0001193125-26-352532:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352531:0
472 shares@ US$26.500.0006% mcap5.0% of flowCommon StockSEC:0001193125-26-352526:0
20,036 sharesCommon StockSEC:0001193125-26-281304:0
11,427 shares0Common StockSEC:0001193125-26-224279:0
36,028 shares@ US$23.750.040% mcap50.0% of flowCommon StockSEC:0001193125-26-224280:0
39,925 shares0Common StockSEC:0001193125-26-088621:0
3,676 shares@ US$19.8553.9% of flowCommon StockSEC:0001193125-26-088620:0
23,000 shares@ US$22.4114.4% of flowCommon StockSEC:0001193125-25-322897:0
10,478 shares@ US$23.00100.0% of flowCommon StockSEC:0001193125-25-288277:0
10,000 shares@ US$21.6572.9% of flowCommon StockSEC:0001193125-25-274502:0
54,021 shares0Common StockSEC:0000950170-25-110715:0
81,346 shares0Common StockSEC:0000950170-25-103206:0
9,737 shares0Common StockSEC:0000950170-25-103196:0
10,371 shares0Common StockSEC:0000950170-25-085534:0
26,502 shares0Common StockSEC:0000950170-25-081079:0
194,347 shares0Common StockSEC:0000950170-25-081078:0
53,004 shares0Common StockSEC:0000950170-25-081076:0
25 of 89 declarations
About Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. is a U.S.-listed healthcare services company trading on the NYSE under ticker MD. The company is based in Sunrise, Florida, in the United States. Its operating history dates back to 1979, and over time it built a national reputation as a physician-led specialist focused on women, newborns and children. In 2022, the company formally renamed itself from Mednax to Pediatrix Medical Group, a brand consolidation intended to create a clearer identity across its affiliated practices and improve recognition among hospitals, clinicians and patients. From a business perspective, Pediatrix is now centered on high-acuity medical services, with core capabilities in neonatology, maternal-fetal medicine and other pediatric subspecialties. The group works through specialized physician teams and contractual arrangements with hospitals and other healthcare facilities, allowing it to deliver both clinical expertise and operational support. Its value proposition is closely tied to quality of care, hospital partnership, cost containment and risk mitigation. The company historically maintained a broad network of affiliated practices across the country. However, its portfolio has been deliberately reshaped in recent periods. According to its 2025 annual report, Pediatrix exited almost all of its affiliated office-based practices in 2024, except for maternal-fetal medicine, and also exited its primary and urgent care service line. This is an important strategic signal: management has been narrowing the business toward more specialized and differentiated service lines rather than trying to operate a broader primary-care platform. In competitive terms, Pediatrix positions itself as a trusted hospital solutions partner with strong clinical depth in maternity, neonatal and pediatric care. Its competitive edge lies in specialty expertise, embedded relationships with hospitals, and the ability to support care quality while helping clients manage staffing, operations and clinical outcomes. The company also emphasizes advanced clinical tools, quality initiatives, training and data-driven processes to support performance. Geographically, Pediatrix is primarily a United States healthcare platform, operating through a nationwide network of physician practices and hospital-based programs. Recent highlights include the 2022 name change, the 2024 portfolio reset, and continued public-facing messaging in 2025 and 2026 around its hospital solutions and pediatric specialty care platform. For investors, Pediatrix is best viewed as a U.S. specialty healthcare operator focused on clinical specialization, operational discipline and a more streamlined business mix, with the NYSE listing adding visibility for international equity market participants.
